ProfessorMedicine ProfessorEpidemiology Adjunct ProfessorHealth Services Co-director, Cardiovascular Health Research UnitFaculty Information Biography Education & Training: PhD, English language and literatureIndiana UniversityBloomington, IN1979 MDIndiana University, School of MedicineIndianapolis, IN1981 Residency in Internal MedicineIndiana University Medical CenterIndianapolis, IN1984 MPHUniversity of WashingtonSeattle, WA1986 Honors: Remington Methodology Lecturer, AHA Epidemiology and Prevention Council2004 School of Public Health and Community Medicine Outstanding Faculty Community Service Award2005 University of Washington Outstanding Public Service Award for Work in Drug Safety2005 Ancel Keys Memorial Lectureship, American Heart Association National Meeting2009 Member, US Food and Drug Administration Science Board2011–2018 Member, National Heart, Lung, Blood Institute Advisory Council2012–2017 Designated Distinguished Scientist by the American Heart Association2013 Elected to the Institute of Medicine of the National Academies of Science2013 University of Washington, School of Public Health Distinguished Alumni Award2018 Member, National Heart, Lung, and Blood Institute Board of External Experts2018– Contact Email: psaty@uw.edu Research & Clinical Interests Research Interests: Myocardial infarction, venous thrombosis, and strokeHypertension, hyperlipidemia, diabetes, and atrial fibrillationPharmacoepidemiologyGenetics, genomics, and pharmacogeneticsEpidemiologic methods Publications Publications: Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620–625. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534–2544. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA. 2008 Apr 16;299(15):1813–7. Psaty BM, O’Donnell CJ, Gudnason V, Kunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E on behalf of the CHARGE Consortiu. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009; 2: 73–80. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, … Psaty BM#, Abecasis GR#, Chakravarti A#, Elliott P#, van Duijn CM#, Newton-Cheh C#, Levy D#, Caulfield MJ#, Johnson T#. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011 Sep 11;478(7367):103–9. #These authors contributed equally.
